Literature DB >> 25187338

Between-subject variability: should high be the new normal?

Hesham S Al-Sallami1, Song Lim Cheah, Shiou Yii Han, Joel Liew, Jin Lim, Mary Anne Ng, Hayneil Solanki, Run Jie Soo, Victoria Tan, Stephen B Duffull.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25187338     DOI： 10.1007/s00228-014-1740-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators.

Authors:  J J Young; D J Kereiakes; C L Grines
Journal:  J Invasive Cardiol       Date:  2000-12       Impact factor: 2.022

Review 2.  New antithrombotics for atrial fibrillation.

Authors:  Luke R E Bereznicki; Gregory M Peterson
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

3.  Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.

Authors:  J J Miceli; K D Wilner; R A Hansen; A C Johnson; G Apseloff; N Gerber
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

Review 4.  Pharmacokinetics--a relevant factor for the choice of a drug?

Authors:  L Z Benet; K Zech
Journal:  Aliment Pharmacol Ther       Date:  1994       Impact factor: 8.171

Review 5.  Clinical pharmacology of lamotrigine.

Authors:  A W Peck
Journal:  Epilepsia       Date:  1991       Impact factor: 5.864
  5 in total
  8 in total

1.  Simplification of a pharmacokinetic model for red blood cell methotrexate disposition.

Authors:  Shan Pan; Julia Korell; Lisa K Stamp; Stephen B Duffull
Journal:  Eur J Clin Pharmacol       Date:  2015-09-26       Impact factor: 2.953

2.  Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates.

Authors:  Mario González-Sales; Nick Holford; Guillaume Bonnefois; Julie Desrochers
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-10-05       Impact factor: 2.745

3.  Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.

Authors:  Jane Knöchel; Karin Nelander; Maria Heijer; Eva-Lotte Lindstedt; Gun-Britt Forsberg; Carl Whatling; Hitoshi Shimada; David S Han; Anders Gabrielsen; Pavlo Garkaviy; Hans Ericsson
Journal:  Clin Drug Investig       Date:  2021-09-21       Impact factor: 2.859

4.  Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections.

Authors:  Christopher M Rubino; Shawn Flanagan
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

Review 5.  Pharmacokinetics of Snake Venom.

Authors:  Suchaya Sanhajariya; Stephen B Duffull; Geoffrey K Isbister
Journal:  Toxins (Basel)       Date:  2018-02-07       Impact factor: 4.546

6.  Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing-Using Rifampicin as an Example.

Authors:  Lina Keutzer; Ulrika S H Simonsson
Journal:  Front Pharmacol       Date:  2020-05-27       Impact factor: 5.810

7.  Dose banding - Weighing up benefits, risks and therapeutic failure.

Authors:  Stephen Duffull
Journal:  Br J Clin Pharmacol       Date:  2022-03-24       Impact factor: 3.716

8.  Estimation of Body Fat Percentage for Clinical Pharmacokinetic Studies in Children.

Authors:  Thomas P Green; Helen J Binns; Huali Wu; Adolfo J Ariza; Eliana M Perrin; Maheen Quadri; Christoph P Hornik; Michael Cohen-Wolkowiez
Journal:  Clin Transl Sci       Date:  2020-11-22       Impact factor: 4.438
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.